<DOC>
	<DOCNO>NCT02722239</DOCNO>
	<brief_summary>The aim study demonstrate bioequivalence fix dose combination Dapagliflozin + Metformin modify -release , film-coated tablet , 10 mg + 1000 mg , ( AstraZeneca AB , Sweden ) versus Forxiga™ ( Dapagliflozin ) , film-coated tablet , 10 mg ( Bristol Myers Squibb Company , USA ) Glucophage® long ( Metformin ) , ER tablet , 1000 mg ( 2 x 500 mg ) ( Merck Santé S.A.S. , France ) already registered Russian Federation .</brief_summary>
	<brief_title>An Open-label , Randomized , Crossover Study Comparative Pharmacokinetics Bioequivalence Dapagliflozin + Metformin , 10 mg + 1000 mg Versus Combined Use Forxiga™ , 10 mg Two Glucophage® Long , ER Tablets , 500 mg Co-administered Healthy Volunteers Under Standard Fed Conditions</brief_title>
	<detailed_description>Randomised open-label crossover comparative , single center , two period , clinical study investigational drug reference drug bioequivalence evaluation single administration study drug ( 1 modify - release film-coated tablet Dapagliflozin + Metformin 1 film-coated tablet Forxiga™ + 2 tablet ER Glucophage® long ) feed condition healthy volunteer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . The volunteer able understand requirement study , sign inform consent form , agree restriction impose course study ; 2 . Male female subject age 1845 , inclusive ; 3 . Caucasian race ; 4 . Bodymass index ( BMI ) within range date 18.5 30 kg/m2 ; 5 . Verified diagnosis `` healthy '' confirm result standard clinical , laboratory , instrumental evaluation ; 6 . A negative pregnancy test Screening Visit female subject childbearing potential . Postmenopausal ( menses least 1 year ) surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) females exempt requirement . In case use hormonal contraceptive , withdraw least 2 month study ; 7 . Volunteers ' preserve reproductive potential agree use adequate contraception throughout study 30 day thereafter 1 . Known hypersensitivity intolerance dapagliflozin metformin excipient study drug ; 2 . History allergy Na+ glucose cotransport inhibitor ; 3 . Complicated allergic history include food intolerance ; 4 . Lactose intolerance , lactase deficiency , glucosegalactose malabsorption ; 5 . Chronic disease cardiovascular , bronchopulmonary , nervous , endocrine , musculoskeletal system , well diseases gastrointestinal tract , liver , kidney , blood , immune system , mental disorder ; 6 . Deviations normal parameter clinical blood count analysis , biochemical blood analysis , urinalysis ; vital sign ; 7 . Mental , physical reason allow subject accord investigator 's opinion ass behavior adequately , follow correctly requirement clinical study protocol ass expect risk possible discomfort ; 8 . Organic brain damage , history increase seizure activity ; 9 . Changes ECG ( clinically significant ) ; 10 . Systolic blood pressure ( AD ) measure sit position , less 100 mmHg 130 mmHg / diastolic blood pressure 70 mm Hg 90 mmHg screening time study ; 11 . Heart rate less 60 80 beat per minute screen prior administration drug period study ; 12 . Scheduled radioisotope radiological examination use iodinated contrast agent &lt; 2 day dose ; 13 . Rare hereditary disease manifestating fructose sorbitol intolerance ; 14 . Gastrointestinal tract surgery ( except appendectomy ) ; 15 . Acute infectious disease le 4 week start study ; 16 . Regular medication ( include dietary supplement combination herbal medicinal product ) vitamin intake within 2 week ( 6 halflives , whichever long ) prior inclusion study subject give agreement refuse medication end study ; 17 . Administration medicine significant effect circulatory dynamic , liver function , etc . ( barbiturate , omeprazol , zimetidin etc . ) less 30 day start study ; 18 . Blood donation ( 450 ml blood plasma ) less 2 month start study ; 19 . Participation another clinical study within 3 month start study ; 20 . Alcohol intake &gt; 10 unit alcohol per week ( 1 unit alcohol 500 ml beer , 200 ml dry wine 50 ml strong alcoholic beverage ) history alcohol abuse , narcomania drug abuse . 21 . Use alcohol and/or caffeinated xanthine containing substance ( example , coffee , tea , cola , energetic drink ) , chocolate well citrus fruit cranberry ( include juice , fruit drink , etc . ) 72 hour prior throughout study . 22 . Smoker ( &gt; 10 cigarette per day ) and/or inability refrain smoking Period I Period II 23 . Special diet ( e.g . vegetarian hypocaloric diet [ less 1000 cal/day ] ) lifestyle ( include night work extreme physical activity , sport weight lift ) , may impede study conduction monitoring ; 24 . Positive screening blood test hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) antibody , human immunodeficiency virus ( HIV1or HIV2 antibody ) / syphilis ( RW ) ; 25 . A positive drug urine screening ( cocaine , opiates , cannabis , barbiturate , amphetamine ) ; 26 . A positive alcohol breath test ; 27 . Dehydration due diarrhea , vomit another cause last 24 hour start study ; 28 . There concern investigator regard safe participation subject study reason ; investigator considers subject ineligible study . 29 . Breastfeeding period ; 30 . For woman Use hormonal contraceptive 2 month study start ; 31 . Female volunteer childbearing potential , unprotected sexual intercourse unsterilized male partner ( i.e. , man sterilize vasectomy least 6 month ) 30 day receive study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Xigduo ;</keyword>
	<keyword>bioequivalence ;</keyword>
	<keyword>crossover ;</keyword>
	<keyword>Russia</keyword>
</DOC>